Nektar Therapeutics (NKTR) Earnings
Nektar Therapeutics is expected to report next earnings on November 5, 2026 (in NaN days), with a consensus EPS estimate of $-2.26. NKTR has beaten EPS estimates in 8 of its last 12 reported quarters (average surprise +24.0% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 13, 2026 | $-1.97 | $-1.23 | +37.6% | $10M | -2.8% |
| May 7, 2026 | $-1.74 | $-1.82 | -4.6% | $11M | +3.9% |
| Mar 12, 2026 | $-2.47 | $-1.78 | +28.1% | $22M | +100.1% |
| Nov 6, 2025 | $-2.85 | $-1.85 | +35.1% | $12M | +12.9% |
| Aug 7, 2025 | $-3.13 | $-2.95 | +5.8% | $11M | +18.7% |
| May 8, 2025 | $-2.70 | $-3.30 | -22.2% | $10M | -31.9% |
| Mar 12, 2025 | $-1.95 | $-2.25 | -15.4% | $29M | -20.4% |
| Nov 7, 2024 | $-0.23 | $-0.18 | +21.7% | $24M | -23.1% |
| May 9, 2024 | $-0.21 | $-0.18 | +14.3% | $22M | +41.1% |
| Mar 4, 2024 | $-0.20 | $-0.22 | -10.0% | $24M | +32.3% |
| Feb 28, 2023 | $-0.45 | $-0.32 | +28.9% | $22M | -0.9% |
| Nov 3, 2022 | $-0.47 | $-0.24 | +48.9% | $24M | +4.5% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q2 FY2026 · August 13, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Core Pipeline Progress for Respeg-Aldisleukin (Respeg) * Initiated the global Zenith AD Phase III registrational program for Respeg in moderate to severe atopic dermatitis (AD) in July 2026; two trials in biologic/JAK inhibitor-naive patients are enrolling, with a third trial in treatment-experienced patients planned to start by end of September 2026. Top-line data is expected in mid-2028, with a BLA submission planned for 2029 if data is positive. * Finalized the design of the single registrational Zenith AA Phase III study for Respeg in alopecia areata following end-of-Phase II alignment with the FDA; study initiation is planned for early 2027, with data expected in H2 2029, and a submission for this second indication planned shortly after the AD BLA. Off-treatment 24-week data from the Phase IIb Resolve AA study is expected in Q4 2026. * An ongoing Phase II study of Respeg in new-onset type 1 diabetes, sponsored by TrialNet, is expected to deliver first cohort data in 2027. Management plans to initiate a new Respeg indication trial before the end of 2026. - Clinical and Product Differentiation * Respeg is a novel upstream Treg agonist that restores immune balance, addressing multiple inflammatory pathways at once rather than blocking single downstream targets; this mechanism allows for deepening responses over time and durable efficacy off-treatment. * Market research with 151 US and European high-volume AD prescribers confirmed strong physician demand for Respeg's differentiated profile: it has no increased infection risk or conjunctivitis (common side effects of current IL-13 inhibitors), offers infrequent quarterly maintenance dosing, and improves comorbid conditions like asthma and allergic rhinitis. Physicians indicated they would prescribe Respeg across first, second, and third-line treatment populations. * For alopecia areata, where the only approved treatments are JAK inhibitors with boxed warnings and high monitoring burden, market research confirmed physician hesitation to prescribe JAKs and preference for Respeg's twice-monthly injectable dosing over daily oral JAKs, with expected higher compliance. - Early Pipeline Progress * Development continues for Nectar 0165, a bivalent TNFR2 agonist antibody for autoimmune indications including MS, ulcerative colitis, and vitiligo. The company is also developing Nectar 0166, a first-in-class bispecific molecule combining TNFR2 agonism with a rheumatology-validated antagonist epitope for multiple autoimmune settings. - Financial Position * Ended Q2 2026 with $1.02 billion in cash and investments, with zero debt on the balance sheet; cash runway extends through Q3 2028, past the mid-2028 AD Phase III data readout. An April 2026 public offering generated $350 million in net proceeds.
Guidance
- Full-year 2026 non-cash royalty revenue is maintained at $40-$45 million. - Full-year 2026 R&D expense guidance is set at $210-$230 million, including $5-$10 million in non-cash depreciation and stock-based compensation; management expects quarterly R&D spending to increase in 2026 as Phase III trials and CMC activities progress. - Full-year 2026 G&A expense guidance is maintained at $60-$65 million, including ~$5 million in non-cash depreciation and stock-based compensation. - Non-cash interest expense for full-year 2026 is expected to total $30-$35 million. - Cash and investments guidance for end-of-2026 was updated to $815-$840 million, upward from prior guidance following the April 2026 public offering. - Key forward catalysts are confirmed as: 24-week off-treatment Resolve AA data in Q4 2026, Zenith AD Phase III top-line data in mid-2028, BLA submission for AD in 2029, and Zenith AA Phase III data in H2 2029.
Segment performance
Nectar Therapeutics is a clinical-stage biotech company with no commercial product segments currently generating material core revenue. The only revenue reported in Q2 2026 was non-cash royalty revenue of $10.1 million, with full-year 2026 total revenue guided to $40-$45 million. Operating expenses are segmented by function: Q2 2026 R&D expenses were $39.1 million (representing 75.3% of total operating expenses), and Q2 2026 G&A expenses were $12.8 million (representing 24.7% of total operating expenses). Full-year 2026 R&D expense is guided to $210-$230 million, and full-year 2026 G&A expense is guided to $60-$65 million. Net loss for Q2 2026 was $40.6 million, or $1.23 per basic/diluted share.
Risks & headwinds
- Forward-looking statements regarding clinical trial outcomes, regulatory approval timelines, and commercial potential are subject to inherent uncertainties, many of which are outside of the company's control. Key risks include potential failure of Phase III trials to meet efficacy or safety endpoints, delays in patient enrollment, and regulatory rejection or delays to approval. * There is ongoing federal litigation scheduled for a jury trial on September 8, 2026 in San Francisco; management declined to comment on ongoing proceedings but stated they believe their position is strong. * Respeg's performance in treatment-experienced AD patients has not yet been confirmed in a large registrational trial, and no well-established placebo benchmark currently exists for this patient population, creating uncertainty for expected efficacy outcomes. * Competition from other developers of novel mechanisms for AD and alopecia areata could impact Respeg's future commercial market share, even if the program is approved. * Clinical trial execution depends on patient recruitment, third-party CRO and supplier performance, and regulatory interactions, all of which carry inherent risk of delays.
Analyst Q&A
Q: What are the expectations for the Q4 2026 off-treatment alopecia areata (AA) Phase IIb data, and how will it inform the Phase III program? /
A: The Phase IIb Resolve AA study enrolled 92 total patients, 31 of whom entered a 16-week extension; all 92 patients will be included in the 24-week off-treatment data readout. The primary goal of this data is to determine the optimal maintenance dosing schedule after 52 weeks of treatment: whether twice every two weeks dosing can be extended to once monthly, which will inform the Phase III long-term extension study design. Off-treatment 52-week data for the AD Phase IIb study will also be released in Q1 2027 to further optimize long-term AD dosing.
Q: How did market research inform Respeg's positioning for first-line versus later-line use in atopic dermatitis, and which patients are prioritized? /
A: Currently only 10% of moderate-severe AD patients receive systemic therapy, creating enormous unmet need. Roughly half of patients on current standard-of-care IL-13 inhibitors fail to respond or lose response over time, making Respeg an ideal second-line option. However, market research shows physicians are very enthusiastic to use Respeg in first-line treatment-naive patients as well, driven by its differentiated safety profile (no infection risk or conjunctivitis) and infrequent quarterly dosing. Management expects Respeg to capture significant share in both first and later-line settings, supporting a broad label indication.
Q: What is your response to recently released data from a competing non-JAK AA therapy, and what is your stance on investigator-sponsored trials (IITs) for additional Respeg indications? /
A: The competing data came from a small, 33-patient open-label single-arm study enrolling a selectively less severe patient population (current episode <4 years), making results difficult to interpret. By contrast, Respeg's Phase IIb was randomized, placebo-controlled, and enrolled a broad patient population (current episode up to 8 years) consistent with prior JAK inhibitor trials, leading to FDA alignment for Phase III. For new indications, management is open to both IITs and company-sponsored pilot proof-of-concept studies, and is currently evaluating opportunities including cutaneous lupus to further demonstrate the value of the Treg agonist mechanism.
Q: What is the expected efficacy of Respeg in biologic-experienced AD patients, and what is the appropriate benchmark for this population? /
A: There is no mechanistic reason why Respeg, as an upstream Treg agonist with a completely different mechanism than IL-13 inhibitors, would not work in patients who failed existing biologic therapies. Per precedent from other AD programs (e.g., leberkizumab in Dupixent-exposed patients), efficacy is expected to be similar between biologic-naive and biologic-experienced patients. There is currently no published placebo-controlled benchmark for this population, so the trial will generate important new data, and including this arm in the registrational program will enable a broad differentiated label for Respeg that covers all patient populations.